NMRD stock jumps to $0.0001 on 02 Feb 2026: intraday top gainer with upside signals
NMRD stock is trading at $0.0001 on NASDAQ in the United States after an intraday rise from $0.000001 to $0.0001, a 9900.00% move that puts the micro-cap among today’s top gainers. Volume is light at 2,201 shares versus an average of 3,472, keeping liquidity a key issue for traders. We examine what drove the spike, the company’s fundamentals, technical signals, and the model forecast that frames potential upside and risks for investors.
NMRD stock intraday move and immediate drivers
NMRD stock jumped to $0.0001 intraday on 02 Feb 2026, lifting market cap to $4,035 (USD) on NASDAQ. One immediate driver is renewed attention to the sugarBEAT wearable and recent coverage on MarketBeat. MarketBeat lists product-focused coverage that likely helped short-term demand.
The move shows high percentage volatility on tiny base pricing. Volume of 2,201 shares remains low, so price swings can magnify with small orders. Traders should expect wide intraday spreads.
Nemaura Medical (NMRD) fundamentals and valuation
Nemaura Medical Inc. operates in Healthcare, Medical – Devices, with sugarBEAT as its core product. The company reports EPS -0.39 (TTM) and no PE ratio. Price to Sales is 0.05, reflecting a minimal market cap relative to reported revenue metrics.
Enterprise Value is listed near $9,929,051, giving an EV/Sales of 128.88, which flags structural valuation and possible balance sheet or reporting anomalies. Shares outstanding are 40,350,000, and cash per share is 0.406184 (TTM). These figures show a company with very low public float value but sizable enterprise measures to watch.
NMRD stock technicals and trading signals
Technical indicators show mixed short-term signals for NMRD stock. RSI sits at 48.16, near neutral. Money Flow Index is 87.98, indicating short-term overbought pressure on low liquidity. The 50-day average price is 0.00013 and the 200-day average is 0.000123, both above current price averages, signaling very small recent downside from slightly higher micro-prices.
On balance, low ATR and tiny absolute price moves mean standard indicators may mislead. Traders should pair indicator reads with volume and order-book depth before entering positions.
Catalysts, upcoming events and NMRD news
Nemaura lists an earnings announcement on 2026-02-27. That is the closest scheduled company event and a likely catalyst for fresh trading interest. Product updates around sugarBEAT adoption or clinical results would also move sentiment quickly.
Recent coverage and search interest are the main short-term news catalysts. For background on product positioning see the company site at Nemaura Medical.
Risks, sector context and Meyka AI grade for NMRD
Key risks for NMRD stock include very low liquidity, negative margins, long receivable days (Days Sales Outstanding 1940.73), and a negative working capital position. Healthcare devices face regulatory and reimbursement hurdles that can slow adoption and revenue scaling.
Meyka AI rates NMRD with a score out of 100: 61.26 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. The grade is informational and not financial advice.
Final Thoughts
NMRD stock’s intraday surge to $0.0001 on NASDAQ highlights how small orders can produce large percentage moves in micro-cap names. Fundamentals show EPS -0.39, market cap $4,035 (USD), and low liquidity with 2,201 shares traded today. Meyka AI’s forecast model projects a one-year price of $0.000543 and a three-year price of $0.000661. Versus the current $0.0001, those figures imply implied upside of 443.16% at one year and 561.05% at three years. Forecasts are model-based projections and not guarantees. Given valuation oddities such as EV/Sales 128.88, the holding case requires conviction on product adoption and improved financials. Short-term traders should weigh high percentage volatility and thin books. Long-term investors should watch the February 27, 2026 earnings release and any sugarBEAT adoption data. We use Meyka AI as an AI-powered market analysis platform for grading and model forecasts, but investors must conduct their own research and consider liquidity and regulatory risks before acting.
FAQs
What caused the NMRD stock spike today?
The intraday spike in NMRD stock came from renewed interest in the sugarBEAT product and fresh coverage on MarketBeat. Low float and light volume (2,201 shares) amplified price moves. Expect news or earnings as likely further catalysts.
Is NMRD stock a buy after the intraday rise?
NMRD stock shows high percentage upside potential in forecasts but carries major liquidity and fundamental risks. Meyka AI grades NMRD 61.26 (Grade B, HOLD). Investors should wait for clearer revenue or clinical progress before buying.
When is the next NMRD earnings report?
Nemaura has an earnings announcement scheduled for 2026-02-27. That report is a key near-term catalyst that could shift NMRD stock sentiment depending on revenue and guidance.
What does the Meyka AI forecast say about NMRD stock?
Meyka AI’s forecast model projects $0.000543 in one year and $0.000661 in three years. Against the current $0.0001, implied upside is 443.16% at one year and 561.05% at three years. Forecasts are projections, not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)